<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02181361</url>
  </required_header>
  <id_info>
    <org_study_id>Xijing-4-3</org_study_id>
    <nct_id>NCT02181361</nct_id>
  </id_info>
  <brief_title>The Secondary Prevention of Nonvalvular Atrial Fibrillation Patients With an Initial Cardioembolic Stroke</brief_title>
  <acronym>CE</acronym>
  <official_title>The Effectiveness and Safety of Aspirin Plus Hirudin in the Secondary Prevention of Cardioembolic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tang-Du Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shaanxi Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Secondary Prevention of patients with an initial cardioembolic stroke associated with
      nonvalvular atrial fibrillation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For the patients with stroke associated with atrial fibrillation,the guidelines recommend
      warfarin as the secondary prevention,but it's disadvantages such as the narrow safety
      scope,high bleeding risk hinder it's utilization in clinical.We divide our trial into two
      groups, the experimental group is aspirin plus Hirudin,the control group is warfarin.We aim
      at comparing two groups'efficacy and safety difference in secondary prevention of atrial
      fibrillation combined stroke.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The recurrence of cardioembolic stroke</measure>
    <time_frame>up to one year after onset</time_frame>
    <description>compare the recurrence rates of the experimental group with the control group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other ischemic cerebrovascular disease</measure>
    <time_frame>one year after onset</time_frame>
    <description>The occurrence of ischemic cerebrovascular disease except cardioembolic stroke</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety</measure>
    <time_frame>one year after onset</time_frame>
    <description>Intracranial hemorrhage and other bleeding events, any death and other serious adverse events causes</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cardioembolic Stroke</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>aspirin plus hirudin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>14 days after stroke occurred, the experimental group gives hirudin two tables three times a day and aspirin 100mg, once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>14 days after stroke occurred,the control group gives an initial dose of 1.5mg,once daily. 3 days later,we check the international normalized ratio(INR) values and adjust the warfarin dose make INR between 2-3 steady.Then, we maintain this warfarin dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin plus hirudin</intervention_name>
    <description>hirudin two tables, three times a day and aspirin 100mg, once daily.</description>
    <arm_group_label>aspirin plus hirudin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>An initial dose of Warfarin is 1.5mg,once daily. 3 days later,we check the international normalized ratio(INR) values and adjust the warfarin dose make INR between 2-3 steady.Then, we maintain this warfarin dose.</description>
    <arm_group_label>Warfarin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older.

          -  Stable condition within 14 days of oneset,Nonvalvular Atrial Fibrillation Patients
             With an Initial Cardioembolic Stroke

          -  Diagnosis need to conform to the Cardioembolic Stroke about clinical and neuroimaging
             and laboratory examination requirements.

        Exclusion Criteria:

          -  Mitral stenosis or previous valvular heart surgery

          -  Admission for acute coronary syndrome or percutaneous coronary intervention within 30
             days

          -  Active infective endocarditis

          -  Purpura disease or blood coagulation disorder

          -  Active bleeding or bleeding tendency

          -  History of intracranial hemorrhage or other serious bleeding events

          -  Confirmed with peptic ulcer disease within 30 days

          -  Esophageal varices

          -  Major surgical procedure or trauma in the previous 30 days

          -  Persistent blood pressure 180/100 mm Hg or greater with or without antihypertensive
             treatment

          -  Requirement for chronic anticoagulant treatment for disorders other than atrial
             fibrillation

          -  Severe liver and kidney function

          -  Allergy for warfarin, aspirin and hirudin

          -  Child bearing potential, pregnancy, or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>wen jiang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Department of Neurology , Xijing Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>wen jiang, MD</last_name>
    <phone>029-84771319</phone>
    <email>jiangwen@fmmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xijing Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2014</study_first_submitted>
  <study_first_submitted_qc>July 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2014</study_first_posted>
  <last_update_submitted>January 21, 2015</last_update_submitted>
  <last_update_submitted_qc>January 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>cardioembolic stroke</keyword>
  <keyword>Hirudin</keyword>
  <keyword>aspirin</keyword>
  <keyword>warfarin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Hirudins</mesh_term>
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

